Hospira recalls another product made at Australian plant cited by FDA

Hospira ($HSP) is recalling another product manufactured at a plant in Australia, which last year received an FDA warning letter. The Lake Forest, IL-based company is voluntarily recalling 3,306 vials of the cancer drug dacarbazine because of discoloration, according to the most recent FDA Enforcement Report. It said the reconstituted solution may appear pink instead of colorless to pale yellow when stored according to labeled conditions. The drug came from its plant in Mulgrave, Victoria, which was issued a warning letter by the FDA in September for its tardiness in investigating out-of-specification test results in some products. One of those products was the cancer med mitoxantrone. Last month, the company began recalling 10 lots of that drug. Report | More

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.